Credit Suisse Ag Precision Biosciences Inc Transaction History

Credit Suisse Ag

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.97 - $45.0 $36,706 - $1.7 Million	37,842 New	37,842 $45,000
Q2 2022 Aug 12, 2022	SELL	$1.15 - $3.34 $35,836 - $104,081	-31,162 Reduced 99.91%	27 $0
Q1 2022 May 16, 2022	BUY	$2.96 - $7.76 $6,062 - $15,892	2,048 Added 7.03%	31,189 $95,000
Q4 2021 Feb 14, 2022	BUY	$7.4 - $11.66 $9,375 - $14,773	1,267 Added 4.55%	29,141 $216,000
Q3 2021 Nov 12, 2021	BUY	$9.18 - $14.15 $60,890 - $93,856	6,633 Added 31.23%	27,874 $321,000
Q2 2021 Aug 16, 2021	SELL	$8.07 - $12.52 $86,913 - $134,840	-10,770 Reduced 33.64%	21,241 $265,000
Q1 2021 May 14, 2021	SELL	$8.57 - $15.79 $357,231 - $658,190	-41,684 Reduced 56.56%	32,011 $332,000
Q4 2020 Feb 12, 2021	BUY	$5.98 - $12.47 $324,528 - $676,734	54,269 Added 279.36%	73,695 $614,000
Q3 2020 Nov 13, 2020	BUY	$4.65 - $8.73 $28,444 - $53,401	6,117 Added 45.96%	19,426 $119,000
Q2 2020 Aug 12, 2020	BUY	$4.66 - $8.7 $62,019 - $115,788	13,309 New	13,309 $111,000

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $539M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.